Boscia senegalensis extract (BSP), a natural SGLT1/2 inhibitor, may lower blood sugar and HbA1c in type 2 diabetes
Punto clave:
A 12-week study in 332 type 2 diabetes patients found that Boscisucrophage (BSP), a natural Boscia senegalensis seed extract, significantly lowered blood glucose and HbA1c when added to existing therapy.
Estudio de un vistazo
Tipo de estudio
Non-randomized CT
duration
Short-Term (≤3 mo)
Intervención
Boscisucrophage
Resultados
Blood glucose, HbA1c, Urine glucose excretion, Body weight
Financiamiento
No financiado por la industria
Qué se estudió
Whether Boscia senegalensis extract (BSP) improves blood sugar control in T2DM
Qué encontraron
- ↓ Blood glucose (significant reduction observed after 1 week of treatment)
- ↓ HbA1c (below 7% after 60 days of treatment)
- ↑ Urine glucose excretion via SGLT1/SGLT2 inhibition
mainEffects
↓ Blood glucose (significant reduction observed after 1 week of treatment)
↓ HbA1c (below 7% after 60 days of treatment)
↑ Urine glucose excretion via SGLT1/SGLT2 inhibition
Evidence Suggest
- BSP significantly reduced blood glucose and HbA1c in T2DM patients resistant to oral antihyperglycemic drugs
- Increased urine glucose excretion (UGE) suggests dual SGLT1/SGLT2 inhibition mechanism
- No significant adverse effects on liver or kidney function were observed
Who this applies to
People with type 2 diabetes who have difficulty controlling blood sugar with oral medications alone, particularly in regions where Boscia senegalensis is traditionally used as a food and medicine source.
Keep in Mind
This was a preliminary single-arm study without a control group, so the results may be influenced by other factors like increased attention or natural disease changes. Randomized controlled trials are needed before firm conclusions can be drawn about BSP's effectiveness compared to standard treatments.
Between the Lines
- Single-arm uncontrolled design limits attribution of effects to BSP alone
- No randomization or blinding introduces potential bias
- BMI was not systematically recorded at baseline, limiting weight-related analysis
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Sources
American Diabetes Association Standards of Care in Diabetes—2025: Pharmacologic Approaches to Glycemic Treatment
Driver's License Information | ADA
Standards of Care in Diabetes—2024
Type 2 diabetes in adults: management
Understanding Type 2 Diabetes | ADA
What Are My Options for Type 2 Diabetes Medications? | ADA
World Health Organization - Diabetes Fact Sheet
NIH National Center for Complementary and Integrative Health - Herbal Supplements for Diabetes
Effectiveness of diet-combined exercise interventions for glycemic control in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.
Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Effect of Nordic Walking on Anthropometrics, Glycemia, and Lipid Profile in Adults With Prediabetes or Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
No ads. No tracking
A clean, privacy-first research experience.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.